DK3936130T3 - Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser - Google Patents

Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser Download PDF

Info

Publication number: DK3936130T3
Authority: DK; Denmark
Prior art keywords: valbenazine; treatment; movement disorders; dosage schedule; hyperkinetic movement
Prior art date: 2014-05-06

Application number

DK21178882.3T

Other languages

Danish (da)

English (en)

Inventor

Christopher O'brien

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-06

Filing date

2015-05-06

Publication date

2024-03-25

2015-05-06 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2024-03-25 Application granted granted Critical

2024-03-25 Publication of DK3936130T3 publication Critical patent/DK3936130T3/da

Links

208000000269 Hyperkinesis Diseases 0.000 title 1
GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
229950006411 valbenazine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychology (AREA)
Dermatology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK21178882.3T 2014-05-06 2015-05-06 Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser DK3936130T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461989240P	2014-05-06	2014-05-06
EP15724438.5A EP3139925B1 (en)	2014-05-06	2015-05-06	Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders

Publications (1)

Publication Number	Publication Date
DK3936130T3 true DK3936130T3 (da)	2024-03-25

Family

ID=53264772

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15724438.5T DK3139925T3 (da)	2014-05-06	2015-05-06	Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
DK21178882.3T DK3936130T3 (da)	2014-05-06	2015-05-06	Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15724438.5T DK3139925T3 (da)	2014-05-06	2015-05-06	Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser

Country Status (24)

Country	Link
US (3)	US20170071932A1 (2)
EP (3)	EP4389227A3 (2)
JP (4)	JP6635945B2 (2)
KR (5)	KR20240011255A (2)
CN (3)	CN112741836A (2)
AU (1)	AU2015256012B2 (2)
CA (1)	CA2947736C (2)
CY (1)	CY1125058T1 (2)
DK (2)	DK3139925T3 (2)
ES (2)	ES2976207T3 (2)
FI (1)	FI3936130T3 (2)
HR (2)	HRP20220025T1 (2)
HU (2)	HUE057839T2 (2)
IL (1)	IL248745B (2)
LT (2)	LT3936130T (2)
MX (1)	MX387625B (2)
NZ (1)	NZ725826A (2)
PL (2)	PL3936130T3 (2)
PT (2)	PT3936130T (2)
RS (2)	RS62782B1 (2)
RU (1)	RU2753740C2 (2)
SI (2)	SI3139925T1 (2)
SM (2)	SMT202400199T1 (2)
WO (1)	WO2015171802A1 (2)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS61645B1 (sr) *	2015-10-30	2021-04-29	Neurocrine Biosciences Inc	Valbenazin ditozilat i njihovi polimorfi
JP6869988B2 (ja)	2015-12-23	2021-05-12	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
US10442800B2 (en)	2016-06-29	2019-10-15	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal forms of NBI-98854, preparation method and use thereof
WO2018102673A1 (en) *	2016-12-02	2018-06-07	Neurocrine Biosciences, Inc.	Use of valbenazine for treating schizophrenia or schizoaffective disorder
US10703750B2 (en)	2017-01-10	2020-07-07	Sandoz Ag	Crystalline valbenazine free base
CA3051830A1 (en)	2017-01-27	2018-08-02	Neurocrine Bioscienes, Inc.	Methods for the administration of certain vmat2 inhibitors
EP3585787A1 (en)	2017-02-27	2020-01-01	Sandoz AG	Crystalline forms of valbenazine salts
WO2018164996A1 (en) *	2017-03-06	2018-09-13	Neurocrine Biosciences, Inc.	Dosing regimen for valbenazine
GB201705303D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705304D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705306D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
CN110678181A (zh) *	2017-04-01	2020-01-10	阿德普蒂奥制药有限公司	(+)-α-二氢丁苯那嗪在治疗运动障碍中的用途
US20190111035A1 (en) *	2017-04-01	2019-04-18	Adeptio Pharmaceuticals Limited	Pharmaceutical compositions
GB201705305D0 (en) *	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705302D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
AU2018241940B2 (en) *	2017-04-01	2023-09-28	Adeptio Pharmaceuticals Limited	Dihydrotetrabenazine for use in the treatment a movement disorder
WO2018200605A1 (en) *	2017-04-26	2018-11-01	Neurocrine Biosciences, Inc.	Use of valbenazine for treating levodopa-induced dyskinesia
CA3076000A1 (en)	2017-09-21	2019-03-28	Neurocrine Biosciences, Inc.	High dosage valbenazine formulation and compositions, methods, and kits related thereto
JP2021502959A (ja)	2017-10-10	2021-02-04	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	特定のｖｍａｔ２インヒビターを投与するための方法
KR20250070134A (ko)	2017-10-10	2025-05-20	뉴로크린 바이오사이언시즈 인코퍼레이티드	특정 vmat2 억제제의 투여 방법
SG11202004165UA (en) *	2017-11-08	2020-06-29	Yuhua Li	Esters of dihydrotetrabenazine
JP7212958B2 (ja)	2017-12-26	2023-01-26	▲蘇▼州科睿思制▲葯▼有限公司	バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
CA3097189A1 (en) *	2018-04-25	2019-10-31	Shinkei Therapeutics Llc	Tetrabenazine transdermal delivery device
GB201808464D0 (en)	2018-05-23	2018-07-11	Adeptio Pharmaceuticals Ltd	Pharmaceutical compounds for use in treating huntington's disease
AU2019287524A1 (en)	2018-06-14	2020-12-24	Neurocrine Biosciences, Inc.	VMAT2 inhibitor compounds, compositions, and methods relating thereto
MA53239A (fr)	2018-08-15	2022-05-04	Neurocrine Biosciences Inc	Procédés d'administration de certains inhibiteurs de vmat2
EP3860599B1 (en)	2018-10-04	2024-05-15	Adeptio Pharmaceuticals Limited	(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MA55893A (fr) *	2019-05-09	2022-03-16	Neurocrine Biosciences Inc	Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2081929B1 (en) *	2006-11-08	2013-01-09	Neurocrine Biosciences, Inc.	Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
EP2083744A4 (en) *	2006-11-09	2013-08-28	Univ New York	DEGRADED GLASS / ZIRCONIUM / GLASS STRUCTURES FOR DAMAGE-RESISTANT DENTAL AND ORTHOPEDIC CERAMIC PROSTHESES
GB2462611A (en)	2008-08-12	2010-02-17	Cambridge Lab	Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en)	2009-08-12	2011-02-17	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
US20110053866A1 (en) *	2008-08-12	2011-03-03	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
CA2972242A1 (en)	2008-09-18	2010-04-22	Auspex Pharmaceuticals, Inc.	Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) *	2010-06-01	2018-07-25	Auspex Pharmaceutical, Inc.	Benzoquinolone inhibitors of vmat2
EP4345100A3 (en)	2012-09-18	2024-04-10	Auspex Pharmaceuticals, Inc.	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CN106061506A (zh) *	2014-02-07	2016-10-26	纽罗克里生物科学有限公司	包含抗精神病药物和vmat2抑制剂的药物组合物及其用途

2015
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending

Also Published As

Publication number	Publication date
IL248745A0 (en)	2017-01-31
AU2015256012B2 (en)	2020-07-23
RS62782B1 (sr)	2022-01-31
SI3936130T1 (sl)	2024-05-31
CN106456629A (zh)	2017-02-22
CA2947736C (en)	2023-04-18
RU2016147523A (ru)	2018-06-08
KR20220140647A (ko)	2022-10-18
HUE066361T2 (hu)	2024-07-28
RU2753740C2 (ru)	2021-08-23
CA2947736A1 (en)	2015-11-12
EP3139925B1 (en)	2021-12-01
PL3936130T3 (pl)	2024-06-10
LT3936130T (lt)	2024-04-25
US20200101063A1 (en)	2020-04-02
MX387625B (es)	2025-03-18
PT3139925T (pt)	2022-01-26
KR20250029267A (ko)	2025-03-04
KR20160147044A (ko)	2016-12-21
CY1125058T1 (el)	2023-06-09
HRP20220025T1 (hr)	2022-04-01
EP3139925A1 (en)	2017-03-15
EP3936130A1 (en)	2022-01-12
EP3936130B1 (en)	2024-02-14
US20210196702A1 (en)	2021-07-01
PT3936130T (pt)	2024-04-17
RS65359B1 (sr)	2024-04-30
ES2976207T3 (es)	2024-07-26
US20170071932A1 (en)	2017-03-16
CN112741836A (zh)	2021-05-04
HUE057839T2 (hu)	2022-06-28
JP2024153782A (ja)	2024-10-29
HRP20240459T1 (hr)	2024-06-21
SMT202200193T1 (it)	2022-07-21
FI3936130T3 (fi)	2024-04-23
MX2016014429A (es)	2017-04-06
EP4389227A3 (en)	2024-09-04
NZ725826A (en)	2023-05-26
LT3139925T (lt)	2022-01-25
JP2019218407A (ja)	2019-12-26
WO2015171802A1 (en)	2015-11-12
JP2017514850A (ja)	2017-06-08
RU2016147523A3 (2)	2018-12-28
AU2015256012A1 (en)	2016-11-24
ES2904526T3 (es)	2022-04-05
KR20240011255A (ko)	2024-01-25
SMT202400199T1 (it)	2024-07-09
EP4389227A2 (en)	2024-06-26
JP2021191799A (ja)	2021-12-16
IL248745B (en)	2022-07-01
SI3139925T1 (sl)	2022-04-29
KR20200133003A (ko)	2020-11-25
CN112741835A (zh)	2021-05-04
DK3139925T3 (da)	2021-12-20
JP6635945B2 (ja)	2020-01-29
PL3139925T3 (pl)	2022-03-21

Publication	Publication Date	Title
DK3936130T3 (da)	2024-03-25	Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser
IL283258A (en)	2021-07-29	Treatment of hypoparathyroidism
IL247452A0 (en)	2016-11-30	Compounds for treatment of complement mediated disorders
DK3125875T3 (da)	2023-07-24	Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
DK3212233T3 (da)	2020-07-27	Kombinationsterapi til behandling af sygdom
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
DK3102213T3 (da)	2020-05-04	Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3492632T3 (da)	2021-03-08	Metoder til behandling af lithiumholdige materialer
DK3119397T3 (da)	2022-03-28	Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3718507T3 (da)	2024-10-28	Anordninger til behandling af nedre ekstremitetsvaskulatur
DK3096741T3 (da)	2020-09-28	Fremgangsmåde til fremstillingen af hybridosomer
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3169328T3 (da)	2022-05-30	Quinolinderivater til behandling af inflammationssygdomme
DK3174858T3 (da)	2019-07-15	Fremgangsmåde til fremstilling af pyrazoler
DK3157534T3 (da)	2022-08-22	Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3237045T3 (da)	2021-05-10	Indretning til indgivelse af lægemidler
DK3148529T3 (da)	2021-12-13	Forbindelser til behandling af hjernecancer
DK3524255T3 (da)	2020-11-09	Sammensætning til behandling af acne
DK3265087T3 (da)	2020-10-19	Fremgangsmåde til behandling med tradipitant
DK3294283T3 (da)	2023-05-30	Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3236960T3 (da)	2025-03-31	Fluralaner til anvendelse i behandling af demodicose
DK3192524T3 (da)	2022-02-14	Hgf præparat egnet til behandling af neurologiske lidelser
DK3302573T3 (da)	2019-11-11	Sammensætning til behandlingen af hjernelæsioner
DK3209295T3 (da)	2021-03-01	Fremgangsmåder til behandling af øjenlidelser
DK3169405T3 (da)	2024-09-23	Fremgangsmåder, forbindelser og sammensætninger til behandling af muskel- og skeletsygdomme